natgillin/translations-raw huggingface dataset:
The reaction mixture went colourless after 5minutes and reaction mixture turned black-green after an additional minute. 
Nakon 5 minuta reakcijska smjesa postane bezbojna, potom crno-zelena nakon dodatne minute.
The method of claim 9, wherein the variable regions of the 1st and the 2nd antibody heavy chains recognize different target epitopes, whereas the variable regions of the 3rd and the 4th antibody heavy chains recognize the same target epitope. 
Postupak u skladu patentnim zahtjevom 7, naznačen time što varijabilne regije prvog i drugog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju različite ciljne epitope, pri čemu varijabilne regije trećeg i četvrtog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju iste ciljne epitope.
A compound according to any one of claims 1-6, wherein any Ar may be substituted with one or more substituents independently selected among halogen, C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl and C1-6-alk(en/yn)yloxy. 
Spoj prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što svako Ar može biti supstituirano sa jednim ili više supstituenata koji su nezavisno izabrani od halogena, Crs-alk(en/injil, halo-C,.g-alk(enfinjil i CLs-alk(en/in)iloksi.
administering to an immune animal a cell which expresses a exogenous protein comprising an extracellular domain of human ILT7 and a exogenous molecule which associates with human ILT7; and 
(1) unošenje u jednu imunu životinju stanice koja izražava egzogenu bjelančevinu koja sadrži izvanstaničnu domenu humanog ILT7 i jednu egzogenu molekulu koja se povezuje s humanim ILT7; i
A composition of claim 2 further comprising a pharmaceutically acceptable carrier. 
Pripravak u skladu s patentnim zahtjevom 7, naznačen time što dodatno sadrži farmaceutski prihvatljiv nosač.
The box is characterized in that, the side walls adjacent to the rear wall feature additional flaps and the splice of said elements has creases, whereat the side wall and the flap feature reverse creases. 
Bočni zidovi koji graniče sa stražnjim zidom imaju dodatne jezičke i spoj navedenih elemenata ima pregibe, a bočni zid i jezičak imaju obrnute pregibce.
The invention also concerns a container unit comprising a collapsible container and a base unit adapted for a dispensing assembly as stated above, wherein said base unit seals a downwardly facing neck part comprising an outlet of the collapsible container, the base unit comprising an outer wall extending axially beyond said neck part in a downwards direction substantially in extension of the wall of the collapsible container, and where a removable aseptic seal covering the outlet is provided. 
Izum se također odnosi na jedinicu spremnika koja obuhvaća sklopivi spremnik i osnovnu jedinicu prilagođenu sklopu za točenje, kako je gore opisano, pri čemu spomenuta osnovna jedinica brtvi vratni dio koji gleda prema dolje i koji obuhvaća izlaz sklopivog spremnika, a osnovna jedinica obuhvaća vanjsku stijenku koja se proteže aksijalno iza spomenutog vratnog dijela u smjeru prema dolje uglavnom u produžetku stijenke sklopivog spremnika, i gdje je predviđena odvojiva aseptična brtva koja pokriva izlaz.
The compound or a salt thereof according to claim 1, wherein L1 is a bond or C1-3 alkylene, L2 is lower alkylene which may be substituted with a substituent selected from Group D1, and R1 is lower alkyl which may be substituted with at least one substituent selected from the group consisting of i) aryl which may be substituted with a substituent selected from Group D2, ii) an aromatic heterocyclic group which may be substituted with a substituent selected from Group D2, and iii) -CO2H, or H, or R1 is combined with a nitrogen atom bonded thereto and an HO2C-L2 group on the nitrogen atom to form 1,2,3,4-tetrahydroisoquinolin-2-yl substituted with at least one -CO2H group, in which Group D1 includes: halogen, 
je H, ili niži alkil koji može biti supstituiran sa supstituentom odabranim iz skupine koja se sastoji od i) arila koji može biti supstituiran sa supstituentom odabranim iz Skupine D2, ii) aromatske heterocikličke skupine koja može biti supstituirana sa supstituentom odabranim iz Skupine D2, i iii) -CO2H, ili se R1 kombinira s HO2C-L2 skupinom kako bi tvorio ciklički amin supstituiran s -CO2H, i Prsten B je naftalendiil, 1,2,3,4-tetrahidronaftalendiil, 2,3-dihidroindendiil, benzotiofenediil, benzofurandiil, ili 2,3-dihidrobenzofurandiil, pri čemu Skupina D1 uključuje: halogen, -OH i -O-niži alkil,
Use according to claim 4, wherein the disease that is generated secondarily as a result of behavior accompanied by itch is cataract, retinal detachment, inflammation, infection or sleeping disorder. 
Upotreba u skladu s patentnim zahtjevom 4, naznačena time što je bolest koja je sekundarna posljedica ponašanja praćenog svrbežom katarakta, odvajanje mrežnice, upala, infekcija ili poremećaj spavanja.
use of the compound of the aforementioned (1) for manufacture of an insulin sensitizer; 
Uporaba, naznačena time, da se koristi spoj prikazan formulom (1)
Examples of embodiments of the combination include: 
Datum objave europskog patenta:
A compound of formula (I), or a salt thereof: wherein 
PATENTNI ZAHTJEVI o Spoj formule (I), ili njegova sol:
The above arrangement is preferred. 
Gore opisani raspored se preferira.
is selected from the group consisting of hydrogen and lower alkyl; a is an integer from 1 to 2; 
R" je izabran iz skupine koja se sastoji od vodika i nižeg alkila; a je cijeli broj od 1 do 2;
The formulation of claim 1, wherein the concentration of the pegylated AvPAL variant is from about 5 to 15 mg/mL. 
uklanjanju slobodnog polietilen-glikola iz pegilirane varijante AvPAL ultrafiltriranjem/dijafiltriranjem; i
The process according to any one of claims 4 to 6, wherein the mechanical treatment in step d) involves pumping of the microorganism-containing fermentation slurry from the fermentation vessel to the hydrolysis vessel. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 6, naznačen time, da mehanička obrada u koraku d) uključuje pumpanje mikroorganizama koji sadrže fermentacijsku kašu iz fermentacijske posude u posudu za hidrolizu.
curing a prokaryotic cell that is auxotrophic for at least one amino acid from at least one amino acid auxotrophy by introducing into the genome of a parent prokaryotic cell a nucleic acid curing an amino acid auxotrophy of the parent prokaryotic cell, 
uklanjanja iz prokariotske stanice koja ima aminokiselinski auksotrof barem jednog aminokiselinskog auksotrofa uvođenjem u genom roditeljske prokariotske stanice nukleinske kiseline koja uklanja aminokiselinski auksotrof roditeljske prokariotske stanice,
The compound according to claim 1, wherein R2 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, optionally wherein R2 is heteroaryl selected from the group consisting of substituted or unsubstituted pyridyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted thienyl, and substituted or unsubstituted furyl. 
Spoj za uporabu prema zahtjevu 1, naznačen time što je R2 supstituirani ili nesupstituirani aril ili supstituirani ili nesupstituirani heteroaril, proizvoljno pri čemu je R2 heteroaril odabran iz skupine koju čine supstituirani ili nesupstituirani piridil, supstituirani ili nesupstituirani piridazinil, supstituirani ili nesupstituirani pirimidinil, supstituirani ili nesupstituirani tienil, i supstituirani ili nesupstituirani furil.
The method of claim 1, wherein 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt is administered to the patient for at least 49 days. 
Derivat alkil etera predstavljen općom formulom [1] ili njegova sol za uporabu u skladu s patentnim zahtjevom 6, naznačen time, da je derivat alkil etera 1-(3-(2-(l-benzotiofen-5-il) etoksi)propil)azetidin-3-ol.
The entire length of the article is overwrapped wish conventional cigarette paper 46. 
Cjela dužina proizvoda je omotana sa konvencionalnim cigaret papirom 46.
the 2'-positions of the purine nucleotides, whether identical or different, are hydroxy groups or substituted by atoms or groups selected from the group consisting of hydrogen atoms, methoxy groups and fluorine atoms; 
2'-pozicije nukleotida purina, bilo iste ili različite, su hidroksi skupine ili su supstituirane atomima ili skupinama odabranima iz skupine koju čine vodikovi atomi, metoksi skupine i atomi fluora;
[SEQ ID NO: 28] GFTFSTYGMH Also preferable is that the antibody, fragment, variant, fusion or derivative comprises a variable heavy chain (VH) in which CDR2 comprises or consists of the amino acid sequence of: 
[SEQ ID NO:28] pri čemu protutijelo ili fragment sadrži varijabilni teški lanac (VH) u kojem CDR2 sadrži ili se sastoji od sekvence amino kiselina:
The pharmaceutical composition of claim 13 wherein the subject is experiencing hyperkalemia, suffering from chronic kidney disease, suffering from congestive heart failure, and/or undergoing dialysis. 
Oralni oblik doziranja prema zahtjevu 14 naznačen time što subjekt ima hiperkalijemiju, pati od kronične bolesti bubrega, pati od kongestivnog zatajenja srca, i/ili se podvrgava dijalizi.
In one embodiment of the methods provided above, the final copper concentration of the supplemented basal cell culture media is between 2 µg/L and 4 µg/L copper. 
(b) kompletiranja osnovnog medija za uzgoj stanica bakrom kako bi se osiguralo konačnu koncentraciju bakra između 2,4 ug/l i 20 ug/l bakra;
capable of proliferating without the presence of an exogenous reprogramming agent for over 1 month; 
- < sposobna je za proliferaciju bez prisustva egzogenog sredstva za reprogramiranje tijekom 1 mjeseca;
said rotatable plug first opening having a first gap at the lowest portion of said first opening; 
predmetnog prvog otvora zapušača (86) koji ima prvi prorez (106) na najnižem dijelu (84) predmetnog prvog otvora (86);
Also preferred are those polymers consisting of block copolymers based on styrene and 1,3-dienes (particularly linear styrene-isoprene-block copolymers of styrene-butadiene-block copolymers), polyisobutylenes, polymers based on acrylate and/or methacrylate. 
Također se preferiraju oni polimeri koji se sastoje od blok kopolimera zasnovanih na stirenu i 1,3-dienu (osobito linearni stirenizopren-blok kopolimeri stiren-butadien-blok kopolimera), poliizobutilene, polimere zasnovane na akrilatu i/ili metakrilatu.
The system of claim 8, wherein the area-array image sensor is a charge coupled device (CCD). 
Sustav prema patentnom zahtjevu 8, naznačen time, da senzor plošne slike od nizova jest nabojski vezani sklop (CCD - Charge coupled device).
Preparation of this solution takes place during continuous mixing at room temperature. 
Priprava ove otopine se odvija uz kontinuirano miješanje na sobnoj temperaturi.
The vaccine of embodiment 42 further comprising an adjuvant. 
Cjepivo prema zahtjevu 14 koje nadalje sadrži adjuvans.
At storage during accelerated conditions, that is at +37°C and at a relative humidity of 80% for a period of 6 months, about 6% of the substance is converted to degradation products. 
Pri skladištenju tijekom ubrzanih uvjeta, tj. na +37*C i pri relativnoj vlažnosti od 80% za period od 6 mjeseci, oko 6% supstancije je konvertirano u proizvode degradacije.
Rb is selected from the group consisting of hydrogen, C1-4 alkyl, and aryl C1-4 alkyl R7 is selected from the group consisting of hydrogen, and C1-4 alkyl; X— is a physiologically acceptable anion, such as chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate. 
Rb se bira iz skupine koju čine vodik, C1-4 alkil 1 aril C1-4 alkil; R7 se bira iz skupine koju čine vodik i C1-4 alkil; X- je fiziološki prihvatljiv anion kojeg se bira iz skupine koju čme klorid, bromid, jodid, hidroksid, sulfat, nitrat, fosfat, acetat, trifluoracetat, fumarat, citrat, tartarat, oksalat, sukcinat, mandelat, metansulfonat i p-toluensulfonat.
applying a first solution that optionally comprises poly (ethylene glycol) and sorbitol to a cation exchange chromatographic material and thereby equilibrating the material, 
- nanošenje prve otopine koja po potrebi obuhvaća poli(etilenglikol) 1 sorbitol za kationsku izmjenu kromatografskog materijala, te time uravnotežavanje materijala,
In some further preferred embodiments, the at least one bacteriophage is selected from the group of virus families consisting of: Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, and Tectiviridae. 
Postupak prema zahtjevu 1, naznačen time da je navedeni bakteriofag odabran iz skupine koju čine obitelji virusa: Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, te
A pharmaceutical aerosol solution composition according to claim 1 wherein the stabilising amount of a mineral acid is an amount of acid equivalent to 1M hydrochloric acid in the range from 0.15 to 0.28 mcg/ml. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 1 ili 2 u kojem stabilizirajuća količina mineralne kiseline jest količina kiseline ekvivalentna 1M klorovodične kiseline u rasponu od 0,15 do 0,28 ug/ul.
Use according to claim 1 wherein the calibrator material 
Uporaba u skladu s patentnim zahtjevom 1 pri čemu materijal kalibratora
The composition of Claim 3, wherein the second therapeutic agent is selected from ritonavir, efavirenz, didanosine, tenofovir disoproxil, nelfinavir mesilate, amprenavir, raltegravir potassium, saquinavir, lopinavir, nevirapine, emtricitabine, abacavir, lamivudine, zidovudine, maraviroc, stavudine, darunavir, fosamprenavir, vicriviroc, a pharmaceutically acceptable salt of any of the foregoing, and combinations thereof. 
Kompozicija prema zahtjevu 10, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, tenofovir-disoproksila, nelfinavir mesilata, amprenavira, kalij-raltegravira, sakvinavira, lopinavira, nevirapina, emtricitabina, abakavira, lamivudina, zidovudina, maraviroka, stavudina, darunavira, fosamprenavira, vicrivirica, farmaceutski prihvatljive soli bilo kojeg od gore navedenih ili njihove kombinacije.
each R12 is selected from H, C1-C6 alkyl, -(C1-C3 alkylene)-C3-C10 cycloalkyl, a 3 to 10 membered carbocyclic group and a 3 to 10 membered heterocyclic group, wherein each of the ring systems is optionally substituted by OH, halo, C1-C3 alkyl and C1-C3 alkoxy; and R14 is H or C1-C6 alkyl. 
do 10-člana karbociklička skupina i 3 do 10-člana heterociklička skupina, gdje je svaki od tih prstenastih sustava opcijski supstituiran s OH, halo, C1-C3 alkil i C1-C3 alkoksi; i je H ili C1-C6 alkil.
The compound of claim 1, wherein R2 and R3 combine with the nitrogen to which they are attached to form optionally substituted azetidinyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se R* i R* kombiniraju s ugljikom na kojeg su vezani kako bi tvorili izborno supstituirani homopiperazinil.
and the compound of formula (II) is a compound of formula (IIa): 
Rs je zaštitna skupina, i gdje je spoj formule (1) je spoj formule (Ia).
The pharmaceutical composition according to claim 40, formulated to provide a daily dosage ranging from 50 mg to 1 g of said lipid compound. 
Farmaceutski pripravak prema zahtjevu 28, naznačen time da je formuliran da osigurava dnevnu dozu od 50 mg do 1 g navedenog lipidnog spoja.
A method for introducing a molecule into the cytosol of a cell, comprising contacting said cell with the molecule to be introduced and a compound as defined in claim 1, and irradiating the cell with light of a wavelength effective to activate the photosensitising agent of the compound thereby releasing the molecule into the cytosol. 
Postupak uvođenja in vitro ili ex vivo molekule u citosol stanice, naznačen time što se sastoji u stavljanju u kontakt navedene stanice s molekulom koju treba uvesti i spojem u skladu s bilo kojim od patentnih zahtjeva 1 do 5, te ozračivanju stanice svjetlom valne duljine koja djelotvorno aktivira fotosenzibilizirajuće sredstvo spoja, čime se molekulu otpušta u citosol.
Next, Formula 37 was deprotected at both the C7 and C10 position to give Formula 38 according to the following reaction: A solution of THF (300 mL) and HCl (22 mL) was added to a solution of Formula 37 (61.8, 52.5mmol) in THF (15 mUg, 920 mL). 
7 Formula 36 Otopina THF (300 mL) i HCI (22 mL) je bila dodana otopini formule 37 (61.8, 52.5 mmol) u THF (15 mL/g, 920 mL).
Generally, these can be antibodies (especially monoclonal antibodies) or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules (such as transferrin), or any other cell binding molecule or substance. 
Molekulski konjugat u skladu s patentnim zahtjevom 3 ili 4, naznačen time što se navedeno sredstvo za vezanje stanica bira između protutijela ili fragmenta protutijela koji sadrži najmanje jedno mjesto vezanja, limfokina, hormona, čimbenika rasta, molekula za prijenos nutricijenata, ili bilo koje druge molekule ili tvari koja se veže na stanice.
A therapeutic composition for use according to claim 1 wherein the series of dose increments consists of 2mg, 5mg, 12.5mg, 25mg, 50mg, 100mg, and 200mg. 
Terapeutski sastav za uporabu prema zahtjevu 1, naznačen time, da se serijska povećanja doze sastoje od 2 mg, 5 mg, 12,5 mg, 25 mg, 50 mg, 100 mg i 200 mg.
Preferably, the endogenous 11- cis -retinal deficiency is associated with Age-Related Macular Degeneration, Leber Congenital Amaurosis (LCA), Retinitis Punctata Albesciens, Congenital Stationary Night Blindness, Fundus Albipunctatus, loss of night vision, contrast sensitivity or Retinitis Pigmentosa. 
Upotreba iz patentnog zahtjeva 17 ili 18, naznačena time, da je deficijencija endogenog 11-cis-retinala povezana sa senilnom makularnom degeneracijom, Leberovom kongenitalnim amaurozom (LCA), retinitis punctata albesciens, kongenitalnim stacionarnim noćnim sljepilom ili fundus albipunctatus.
In addition, the protein(s) according to the invention can be administered together with other components of biologically active agents such as pharmaceutically acceptable surfactants, excipients, carriers, diluents and vehicles. 
Dodatno, protein(i) se sukladno izumu mogu davati zajedno s drugim komponentama biološki aktivnih tvari poput farmaceutski prihvatljivih surfaktanata, ekscipijenata, nosača, diluenata i otapala.
A pharmaceutical composition comprising at least one antigen binding protein of claim 1, 2, or 3 and a pharmaceutically acceptable excipient. 
Farmaceutski sastav sadrži najmanje jedan protein koji veže antigen iz bilo kojeg od patentnih zahtjeva 1-5 i farmaceutski prihvatljivi ekscipijens.
Use of a composition comprising a GPR119 agonist and a DPP-IV inhibitor for the manufacture of a medicament for the treatment or prevention of diabetes or a condition related thereto. 
Uporaba pripravka u skladu sa zahtjevom 1, naznačena time, da se koristi za izradu lijeka za liječenje ili prevenciju dijabetesa ili stanja povezanih s njim.
The compound for use according to claim 18 wherein said disease is osteoarthritis, restenosis, atherosclerosis, bone disorders, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, angiogenesis, pancreatitis, kidney disease, inflammatory bowel disease, or multiple sclerosis. 
Spoj za upotrebu prema zahtjevu 18 naznačen time da je bolest osteoartritis, restenozis, arteroskleroza, poremećaj kosti, dijabetski retinopatitis, psorijaza, benigno uvećanje prostate, angiogeneza, pankreatitis, bolest bubrega, upalna bolest crijeva, ili multipla-skleroza.
Of course, the size of the particles with a conductive coating thickness depends on the thickness of the top coating. 
Naravno, veličina čestica s debljinom vodljivog sloja ovisi od debljine gornjeg sloja.
90b) (2-Chloro-4-methanesulfonyl-phenyl)-methanol: To a stirred dispersion of 2-chloro-4-methanesulfonyl-benzaldehyde (25 g, 0.11 mol) in absolute ethanol (120 ml) is added sodium borohydride (4.6 g, 0.12 mol) whilst cooling with an ice-bath to maintain room temperature. 
U miješanu disperziju 2-klor-4-metansulfonil-benz-aldehida (25 g, 0,11 mola) u apsolutnom etanolu (120 ml) doda se natrijev borhidrid (4,6 g, 0,12 mola) uz hlađenje s ledenom kupelji da se održi na sobnoj temperaturi.
represents a side chain of an amino acid residue selected from Ser and Thr, optionally substituted with alkyl or acyl; 
predstavlja bočni lanac u aminokiselinskom ostatku Ser ili Thr, izborno supstituiran alkilom ili acilom;
The modified soluble FGF receptor Fc fusion of claim 8, wherein the KD value of said fusion for FGF2 measured by Biacore™ is around 1.5 nM. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s patentnim zahtjevom 8, naznačena time što vrijednost Kp kod navedene fuzije za FGF2, prilikom mjerenja pomoću BiacoreT", je otprilike 1,5 nM.
The process of claim 10, wherein the industrial process is one of a metal finishing process, a metal etching process, a metal extraction process, a mineral processing process, a coal seam gas extraction process, a shale gas extraction process, or a shale oil extraction process. 
Postupak prema zahtjevu 10 naznačen time što industrijski postupak je postupak završne obrade metala, postupak metalnog jetkanja, postupak ekstrakcije metala, proces prerade minerala, proces ekstrakcije plina iz ugljena, postupak ekstrakcije plina iz škriljca ili postupak ekstrakcije nafte iz škriljca.
a hemoglobinopathy, an inherited metabolic disorder, a disease that necessitates an organ transplant, particularly wherein the organ is heart, skin, liver, lung, heart and lung, kidney, pancreas, or an endocrine organ, particularly wherein the endocrine organ is a thyroid gland, parathyroid gland, a thymus, adrenal cortex, or adrenal medulla, 
Pripravak za uporabu prema zahtjevu 1, naznačen time da primatelj ima bolest, osobito gdje je bolest izabrana iz skupine koju čine: autoimune bolesti, osobito dijabetes, multiple skleroza, ili sistemski eritemski lupus, leukemija, hemoglobinopatija, naslijeđeni poremećaj metabolizma, bolest koja zahtijeva transplantaciju organa, osobito gdje je organ srce, koža, jetra, pluća, srce i pluća, bubreg, gušterača, ili endokrini organ, osobito gdje je endokrini organ štitnjača, paratiroidna žlijezda, timus, kora ili srž nadbubrežne žlijezde, infekcija imunodeficijentnim virusom ili hepatitisom, i hematopoetska malignost, anemija, hemoglobinopatija, i nedostatak enzima.
The orthopedic screw of claim 2, further comprising at least one facet disposed on shaft of the screw between adjacent threads. 
5. < Ortopedski vijak u skladu s patentnim zahtjevom 1, naznačen time što nadalje sadrži najmanje jednu facetu, koja se nalazi na tijelu vijka, između susjednih navoja.
to a second compound of formula: 
O u drugi spoj formule: um
The pharmaceutical composition for use according to claim 13, wherein the cancer is colorectal cancer. 
Farmaceutski sastav za uporabu prema zahtjevu 13, gdje je karcinom kolorektalni karcinom.
The method according to claim 1, wherein the ternesite clinker is ground to a degree of fineness (according to Blaine) ranging from 2000 cm2/g to 6000 cm2/g. 
Postupak sukladno barem jednom od zahtjeva 1 do 6, naznačen time što je sirova smjesa za hranu samljevena na finoću od 1500 do 10000 cm'/g, poželjno od 2000 do 4000 cm?/g.
The method according to claim 1, further comprising passivating the polished surfaces with nitric acid. 
Postupak u skladu s patentnim zahtjevom 3 ili 4, naznačen time što se polirane površine pasiviziraju dušičnom kiselinom.
Plasticizers according to the invention are preferably selected from among triethyl citrate, polyethylene glycol, polypropylene glycol, glycerol monostearate, polyols, glycerine, vegetable oils and/or a mixture thereof. 
Pripravak u skladu s patentnim zahtjevom 9, naznačen time što se navedeni plastifikatori biraju između trietilcitrata, polietilen-glikola, polipropilen-glikola, glicerol-monostearata, poliola, glicerola, biljnih ulja i/ili njihove smjese.